Pemetrexed Followed by Docetaxel or in Reverse Sequence

Summary

Both pemetrexed and docetaxel have been reported to have similar activity against non-small cell lung cancer (NSCLC) who failed previous chemotherapy in a large randomized phase III study. However, no study showed different toxicity and efficacy profiles within individual patients. Present phase II randomized clinical trial is designed to answer these questions, with addition of information about whether or not sequential therapy can prolong disease-free and overall survival.

Timeline

Start

2008-03

Primary completion

2009-09

Completion

2009-09

Drugs

Indications